What did @acenc910 actually say?
After one week on what they call "the GOP one" (clearly GLP-1), this creator says they experienced only mild, ambiguous nausea on a 1.5 mg starting dose, then jumped to 4 mg after just one week with their doctor's approval. They're taking an oral pill form, not injections. They flagged constipation as a concern they'd heard about, said they're loading up on fiber and protein to counter it, and noted zero weight loss so far. Pretty honest, pretty measured for a week-one TikTok update.
The video doesn't make dramatic claims. There's no "I lost 10 pounds in a week" energy here. What it does do is casually describe a dose escalation timeline that's faster than standard clinical protocols, and that's worth unpacking.
Does the science back this up?
Mostly, yes, but the dose escalation piece deserves scrutiny. The oral GLP-1 they're describing sounds like oral semaglutide (Rybelsus), which starts at 3 mg, not 1.5 mg, so there's some confusion about what they're actually taking. That matters.
Standard Rybelsus titration per FDA labeling goes 3 mg for 30 days, then 7 mg for 30 days, then 14 mg if needed. Moving from a starter dose to a higher dose in one week is not the standard protocol. The PIONEER trials (Aroda et al., 2019, Lancet) that established oral semaglutide's efficacy used monthly titration specifically to minimize gastrointestinal side effects. Faster titration increases GI risk. That said, if a licensed physician reviewed the patient's tolerance and made a clinical judgment call, that's within the scope of medical practice. It's just not what the evidence base was built on.
On constipation: they're right that it's real. A 2022 meta-analysis by Shi et al. in Obesity Reviews found constipation affected roughly 5 to 11 percent of patients on semaglutide across trials. Fiber and hydration are genuinely the right countermeasures.
What did they get wrong (or right)?
Let's be direct. The dose numbers don't add up. Oral semaglutide (Rybelsus) comes in 3 mg, 7 mg, and 14 mg tablets. A 1.5 mg dose and a 4 mg dose don't correspond to any FDA-approved oral semaglutide formulation. This could mean they're on a compounded oral GLP-1 product, which is a different animal entirely. Compounded semaglutide is not FDA-approved, has not been tested in the same clinical trials, and cannot be assumed to be equivalent to Rybelsus in absorption, safety, or efficacy. That distinction matters and they don't mention it.
What they got right: acknowledging that the starter dose is low and effects may not be felt yet is accurate. Pointing to fiber and protein as protective strategies is legitimate dietary advice consistent with clinical guidance. And being honest that they haven't seen weight loss at week one is refreshingly realistic. Most GLP-1 weight loss in trials doesn't show up meaningfully until weeks four through eight (Davies et al., 2021, New England Journal of Medicine).
What should you actually know?
If you're considering oral GLP-1 therapy, the dose numbers in this video are a red flag worth paying attention to. FDA-approved oral semaglutide does not come in 1.5 mg or 4 mg strengths. If someone's taking those doses, they're almost certainly on a compounded product. Compounded GLP-1 medications have been under significant FDA scrutiny. The agency issued warnings in 2023 and 2024 about compounded semaglutide products, including concerns about dosing accuracy and safety data gaps.
The creator's instinct to stay on a starter dose before escalating is clinically sound. Their doctor's decision to escalate in one week rather than one month is outside typical guidelines, though not necessarily harmful if the patient is truly asymptomatic. The STEP trials used 4-week titration windows for a reason: GI side effects are dose-dependent and time-dependent.
No weight loss at week one is completely normal and expected. Anyone telling you they dropped significant weight in the first seven days on a GLP-1 is either misattributing water weight or embellishing. Realistic expectations matter for adherence.
- Fiber intake is genuinely useful for GI side effects, including both constipation and nausea management on GLP-1s.
- Protein preservation matters because GLP-1s can cause muscle loss alongside fat loss, especially without resistance training.
- Going to the gym, as the creator mentions, is evidence-based: Wilding et al. (2021, NEJM) noted exercise helps preserve lean mass during GLP-1 weight loss.